Fecal Lactoferrin Is a Sensitive and Specific Marker of Disease Activity in Children and Young Adults With Inflammatory Bowel Disease
- 1 April 2007
- journal article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 44 (4), 414-422
- https://doi.org/10.1097/mpg.0b013e3180308d8e
Abstract
Fecal lactoferrin (FLA) is a neutrophil-derived surrogate marker of intestinal inflammation that is elevated in patients with inflammatory bowel disease. However, the correlation between FLA levels and serological markers of disease activity has not been previously reported, to our knowledge. In the present study we evaluated the ability of FLA levels to reflect disease activity in pediatric patients with inflammatory bowel disease. We further assessed the relationship between FLA levels and customary laboratory and clinical measures of inflammation. Fecal specimens were collected from 148 consecutive pediatric patients (79 with Crohn disease, 62 with ulcerative colitis, and 7 with irritable bowel syndrome) and 22 healthy control individuals. Lactoferrin was measured by enzyme-linked immunosorbent assay (IBD-SCAN, TECHLAB, Inc). Disease activity was assessed at the time of sample provision by laboratory measures (including erythrocyte sedimentation rate [ESR] and albumin) and previously validated disease activity indices (Pediatric Crohn Disease Activity Index, Kozarek, Harvey Bradshaw Activity Index). Lactoferrin levels were significantly higher in patients with ulcerative colitis (1880 ± 565 μg/mL) (mean ± SE) or Crohn disease (1701 ± 382 μg/mL) than in healthy control individuals under 21 years of age (1.17 ± 0.47 μg/mL, P < 0.001). Lactoferrin levels correlated significantly with ESR, hematocrit, albumin, and platelet count (P < 0.001). Receiver operating characteristic curve analysis revealed that FLA levels were comparable to ESR in detecting patients with clinically active disease (P < 0.001). Patients who experienced a clinical flare within 2 months of specimen collection displayed higher lactoferrin levels (845 ± 452 μg/mL) than did those who remained in clinical remission (190 ± 90 μg/mL, P = 0.003). Data presented here demonstrate that FLA is a sensitive and specific biochemical marker of inflammation for use in the diagnosis and interval assessment of pediatric patients with IBD, and its level correlates well with both clinical disease activity indices and ESR. Elevated levels of FLA may also identify patients at greater risk for the development of subsequent clinical flares.Keywords
This publication has 46 references indexed in Scilit:
- Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel diseaseScandinavian Journal of Gastroenterology, 2004
- Fecal Lactoferrin Is A Sensitive and Specific Marker in Identifying Intestinal InflammationAmerican Journal Of Gastroenterology, 2003
- Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteinsThe American Journal of Gastroenterology, 2002
- Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor‐α, in the treatment of Crohn’s disease: is its efficacy augmented by steroid‐sparing immunosuppressive therapy?Internal Medicine Journal, 2001
- Human Lactoferrin Interacts with Soluble CD14 and Inhibits Expression of Endothelial Adhesion Molecules, E-Selectin and ICAM-1, Induced by the CD14-Lipopolysaccharide ComplexInfection and Immunity, 2000
- A Randomized, Double-Blind Study of the Effect of Olestra on Disease Activity in Patients With Quiescent Inflammatory Bowel DiseaseAmerican Journal Of Medicine, 1997
- Lactoferrin: Molecular Structure and Biological FunctionAnnual Review of Nutrition, 1995
- Evaluation of a New Latex Agglutination Test for Fecal Lactoferrin in Travelers' DiarrheaJournal of Travel Medicine, 1994
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980